Vaccibody AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more
Vaccibody AS (5VB) - Net Assets
Latest net assets as of September 2025: €99.25 Million EUR
Based on the latest financial reports, Vaccibody AS (5VB) has net assets worth €99.25 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€105.70 Million) and total liabilities (€6.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €99.25 Million |
| % of Total Assets | 93.9% |
| Annual Growth Rate | 44.23% |
| 5-Year Change | -23.84% |
| 10-Year Change | N/A |
| Growth Volatility | 180.46 |
Vaccibody AS - Net Assets Trend (2018–2024)
This chart illustrates how Vaccibody AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vaccibody AS (2018–2024)
The table below shows the annual net assets of Vaccibody AS from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €136.21 Million | -20.46% |
| 2023-12-31 | €171.26 Million | +9.07% |
| 2022-12-31 | €157.02 Million | -19.09% |
| 2021-12-31 | €194.06 Million | +8.50% |
| 2020-12-31 | €178.85 Million | +487.61% |
| 2019-12-31 | €30.44 Million | +101.25% |
| 2018-12-31 | €15.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vaccibody AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1044700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €144.98 Million | 106.43% |
| Total Equity | €136.21 Million | 100.00% |
Vaccibody AS Competitors by Market Cap
The table below lists competitors of Vaccibody AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Banestes S.A - Banco do Estado do Espírito Santo
SA:BEES3
|
$37.47 Million |
|
Global InterConnection Group Limited
F:9OD
|
$37.47 Million |
|
Skyharbour Resources Ltd
OTCQX:SYHBF
|
$37.48 Million |
|
Go Hub Capital Berhad
KLSE:0311
|
$37.48 Million |
|
China Everbright Greentech Limited
F:CK7
|
$37.46 Million |
|
InspireMD Inc
NASDAQ:NSPR
|
$37.44 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
$37.44 Million |
|
Index Living Mall Public Company Limited
BK:ILM
|
$37.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaccibody AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 171,259,000 to 136,214,000, a change of -35,045,000 (-20.5%).
- Net loss of 38,821,000 reduced equity.
- Other factors increased equity by 3,776,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-38.82 Million | -28.5% |
| Other Changes | €3.78 Million | +2.77% |
| Total Change | €- | -20.46% |
Book Value vs Market Value Analysis
This analysis compares Vaccibody AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.28x to 0.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €0.05 | €0.23 | x |
| 2019-12-31 | €0.11 | €0.23 | x |
| 2020-12-31 | €0.63 | €0.23 | x |
| 2021-12-31 | €0.67 | €0.23 | x |
| 2022-12-31 | €0.53 | €0.23 | x |
| 2023-12-31 | €0.52 | €0.23 | x |
| 2024-12-31 | €0.42 | €0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaccibody AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -447.30%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.13x
- Recent ROE (-28.50%) is below the historical average (-13.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -48.41% | -49517.87% | 0.00x | 1.19x | €-8.83 Million |
| 2019 | -49.11% | -26911.15% | 0.00x | 1.09x | €-17.99 Million |
| 2020 | 83.74% | 69.66% | 0.93x | 1.29x | €131.89 Million |
| 2021 | -4.85% | -27.72% | 0.13x | 1.37x | €-28.82 Million |
| 2022 | -27.22% | -596.30% | 0.03x | 1.41x | €-58.44 Million |
| 2023 | -20.53% | -272.47% | 0.06x | 1.22x | €-52.28 Million |
| 2024 | -28.50% | -447.30% | 0.06x | 1.13x | €-52.44 Million |
Industry Comparison
This section compares Vaccibody AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaccibody AS (5VB) | €99.25 Million | -48.41% | 0.06x | $37.47 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |